Off-label use of drugs and medical devices: a review of policy implications
Clinical Pharmacology & Therapeutics, 04/13/2012
Given the contradictory and unresolved expectations of major stakeholders, off–label use remains problematic. It requires a new policy paradigm that can successfully balance the need for innovation against the imperatives of evidence–based practice and finite health–care resources.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.